InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) was the recipient of a large drop in short interest in June. As of June 15th, there was short interest totaling 445,268 shares, a drop of 63.0% from the May 31st total of 1,202,243 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
InnoCare Pharma Price Performance
Shares of InnoCare Pharma stock remained flat at $1.55 during trading on Tuesday. InnoCare Pharma has a 12 month low of $1.55 and a 12 month high of $2.31. The firm’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $1.74.
Analysts Set New Price Targets
Separately, Morgan Stanley raised InnoCare Pharma to an “overweight” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy”.
About InnoCare Pharma
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
Featured Articles
- Five stocks we like better than InnoCare Pharma
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
